🔗 Share this article

During a tenure as head of the WHO, a past official famously stated that all of the “easy” antibiotics had long since been discovered. The argument was that in tackling the pressing threat of drug-resistant infections, we would face difficulties to discover new medicines – or conserve the existing ones – without developing new ways of operating. This view was accurate.

A Slow and Challenging Development Path

Since 2017, just 16 antibiotics have received widespread regulatory approval – mostly similar derivatives of drugs already in use and thus not expected to evade bacterial resistance for an extended period. The development of new ones is a lengthy and unprofitable business, given that curative medicines are less lucrative as ones managing longer-term ailments. The overall prospect continues to be grim.

A Glimmer of Optimism and a Novel Approach

Nevertheless, the recent announcement of a pair of novel FDA-approved antibiotics for gonorrhea is good news and, importantly, validates a innovative method of encouraging development. A particular of the new drugs, a compound called Zoliflodacin, is the result of a novel kind of partnership between a Swiss non‑profit and a drug firm. The non-profit supplied financial support and organised clinical trials to defray costs and clear approval processes. This sort of support in advance helps steer the industry towards areas of greatest global need.

This model and another praised revenue guarantee scheme – launched to guarantee income to companies that invest in certain antibiotics – constitute the best hope of maintaining a trickle of novel treatments from the existing framework.

The Inevitable Problem of Resistance

But even hurrying the production of compounds in the pipeline is not enough. Zoliflodacin is at times categorized as a novel type of antimicrobial, indicating it attacks a component of the infectious bacteria that no other drug does, in principle forcing the pathogen to start from zero in developing a defense to it. Researchers and physicians are grateful to have a new option for gonorrhoea – which has strains resistant to all existing treatments – but warn that eventual drug resistance to it is inevitable.

As has become the norm with new antibiotics, exists consequently an debate about whether it should be held in reserve, restricted to highly resistant cases only – confining its application to settings where sophisticated diagnostics is accessible. This kind of prudent strategy should be the global standard, but frequently cannot be implemented readily in many regions.

A Diminishing Stream of Discovery

On a wider scale, it is difficult to see where the stream of additional new antibiotics we require could possibly originate. The former official's comment nodded to the fact that surveying the natural world for biological compounds – as with the first antibiotic – has had diminishing returns. Use of AI has been proposed to accelerate the discovery process, although a much-celebrated initial discovery identified in recent years has not yet advanced past animal trials. Fully lab-created compounds, which are mainly or fully lab-created, are constantly in research, but often confront the iron laws of chemistry – the fact that we imagine a molecule does not guarantee we can create it easily.

Running Fast to Stand Still

The prevailing scientific evaluation is that when it comes to antimicrobials, we must move with great speed truly just to remain in the same place. Prudent, internationally coordinated use is the sole method to maintain our advantage. Regrettably, the scale of future discoveries is likely to seem miserly in contrast to the curative bonanza of the previous century.